BR0112359A - Derivados de aminoácidos aza-bicìclicos ligados por ponte como antagonistas de integrina alfa4 - Google Patents

Derivados de aminoácidos aza-bicìclicos ligados por ponte como antagonistas de integrina alfa4

Info

Publication number
BR0112359A
BR0112359A BR0112359-9A BR0112359A BR0112359A BR 0112359 A BR0112359 A BR 0112359A BR 0112359 A BR0112359 A BR 0112359A BR 0112359 A BR0112359 A BR 0112359A
Authority
BR
Brazil
Prior art keywords
bridge
amino acid
compounds
acid derivatives
aza
Prior art date
Application number
BR0112359-9A
Other languages
English (en)
Inventor
Alexey B Dyatkin
Bruce E Maryanoff
William J Hoekstra
Wei He
William A Kinney
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of BR0112359A publication Critical patent/BR0112359A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE AMINOáCIDOS AZA-BICìCLICOS LIGADOS POR PONTE COMO ANTAGONISTAS DE INTEGRINA ALFA4". A invenção direciona-se a compostos aza-bicíclicos ligados tendo a Fórmula (I): Fórmula (I) e sais farmaceuticamente aceitáveis dos mesmos. Os compostos são antagonistas receptores de integrina <244>4 úteis e, em particular, antagonistas receptores de integrina <244>4<225>1 e <244>4<225>7, A invenção além disso direciona-se a métodos para uso dos compostos presentes para tratar distúrbios mediados por integrina incluindo, mas não limitado a, distúrbios inflamatórios, distúrbios auto-imunes e distúrbios proliferadores de célula, métodos para preparar os compostos e métodos para preparar os intermediários, derivados e composições farmacêuticas dos mesmos.
BR0112359-9A 2000-06-30 2001-06-29 Derivados de aminoácidos aza-bicìclicos ligados por ponte como antagonistas de integrina alfa4 BR0112359A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21569500P 2000-06-30 2000-06-30
US09/891,602 US6960597B2 (en) 2000-06-30 2001-06-26 Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
PCT/US2001/020857 WO2002002556A2 (en) 2000-06-30 2001-06-29 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS

Publications (1)

Publication Number Publication Date
BR0112359A true BR0112359A (pt) 2003-05-27

Family

ID=26910288

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112359-9A BR0112359A (pt) 2000-06-30 2001-06-29 Derivados de aminoácidos aza-bicìclicos ligados por ponte como antagonistas de integrina alfa4

Country Status (19)

Country Link
US (1) US6960597B2 (pt)
EP (1) EP1303492A2 (pt)
JP (1) JP2004506612A (pt)
KR (1) KR20030014287A (pt)
CN (1) CN1449385A (pt)
AR (1) AR031853A1 (pt)
AU (1) AU2001273095A1 (pt)
BR (1) BR0112359A (pt)
CA (1) CA2415088A1 (pt)
HK (1) HK1052343A1 (pt)
HU (1) HUP0301195A2 (pt)
IL (1) IL154053A0 (pt)
MX (1) MXPA03000814A (pt)
NO (1) NO20026252L (pt)
NZ (1) NZ523852A (pt)
PL (1) PL359997A1 (pt)
RU (1) RU2003102631A (pt)
WO (1) WO2002002556A2 (pt)
YU (1) YU98902A (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
AU7874001A (en) 2000-08-18 2002-03-04 Ajinomoto Kk Novel phenylalanine derivatives
DE60124573T2 (de) 2000-09-29 2007-06-21 Ajinomoto Co., Inc. Neue phenylalanin-derivate
US7115628B2 (en) * 2001-07-18 2006-10-03 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
CA2514125A1 (en) * 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US20050176755A1 (en) * 2003-10-31 2005-08-11 Dyatkin Alexey B. Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
EP2615087A3 (en) 2003-12-22 2013-08-07 Ajinomoto Co., Inc. Phenylalanine derivatives
WO2005077915A1 (en) * 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. Pyridazinones as antagonists of a4 integrins
BRPI0506676A (pt) * 2004-02-10 2007-05-15 Janssen Phamaceutica N V piridazinona uréias como antagonistas de integrinas alfa4
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
KR20070029733A (ko) 2004-06-04 2007-03-14 제넨테크, 인크. 다발성 경화증의 치료 방법
WO2006096807A1 (en) * 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
CA2619402C (en) * 2005-08-15 2015-02-03 Boehringer Ingelheim International Gmbh Method for producing betamimetics
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CA2781390A1 (en) * 2009-12-14 2011-06-23 Inspire Pharmaceuticals, Inc. Bridged bicyclic rho kinase inhibitor compounds, composition and use
WO2011094890A1 (en) * 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
AU2013215332A1 (en) 2012-01-31 2014-09-04 Genentech, Inc. Anti-Ig-E M1' antibodies and methods using same
US8877775B2 (en) 2013-03-14 2014-11-04 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
ES2845473T3 (es) 2013-03-14 2021-07-26 Boehringer Ingelheim Int (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
ES2864349T3 (es) * 2013-06-11 2021-10-13 Receptos Llc Nuevos moduladores del receptor GLP-1
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
WO2016038007A1 (en) 2014-09-12 2016-03-17 Boehringer Ingelheim International Gmbh Spirocyclic inhibitors of cathepsin c
KR20180075537A (ko) 2015-10-06 2018-07-04 제넨테크, 인크. 다발성 경화증을 치료하기 위한 방법
EP3939989A1 (en) 2016-11-11 2022-01-19 Zealand Pharma A/S Cyclic peptides multimers targeting alpha 4beta 7 integrin
CN112969504B (zh) * 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905971A (en) * 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
JPS6314774A (ja) 1986-07-07 1988-01-21 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
US6090785A (en) * 1992-10-15 2000-07-18 Merck & Co., Inc. Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
US5523308A (en) * 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827860A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5827866A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
JP2002512625A (ja) 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
US6221888B1 (en) * 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
DE69833654T2 (de) 1997-05-29 2006-12-14 Merck & Co., Inc. (A New Jersey Corp.) Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
US6291511B1 (en) * 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
KR20010022413A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 벤질화합물
CA2291475A1 (en) 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
EP1001973A1 (en) 1997-07-31 2000-05-24 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6229011B1 (en) * 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
DK1005445T3 (da) 1997-08-22 2004-10-04 Hoffmann La Roche N-alkanoylphenylaninderivater
PT1005446E (pt) 1997-08-22 2004-06-30 Hoffmann La Roche Derivados de n-aroilfenilalanina
US6455550B1 (en) * 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
EP1027328B1 (en) * 1997-10-31 2006-08-23 Aventis Pharma Limited Substituted anilides
US6191171B1 (en) * 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE69919334T2 (de) 1998-02-26 2005-08-04 Celltech Therapeutics Ltd., Slough Phenylalaninderivate als inhibitoren von alpha4 integrinen
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
US6121280A (en) 1998-03-24 2000-09-19 Pfizer Inc. Azabicyclic rotomase inhibitors
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821406D0 (en) 1998-10-01 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
ATE299490T1 (de) 1999-01-22 2005-07-15 Elan Pharm Inc Multizyklische verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion
US6436904B1 (en) * 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) * 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
SK10742001A3 (sk) * 1999-01-27 2002-08-06 Ortho-Mcneil Pharmaceutical, Inc. Peptidylové heterocyklické ketóny použiteľné ako inhibítory tryptázy
PT1154993E (pt) * 1999-02-18 2005-01-31 Hoffmann La Roche Derivados de tioamida
EP1161416B1 (en) * 1999-03-01 2004-04-14 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 - receptor antagonists
AU6903200A (en) * 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
AU6909300A (en) * 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
US20030130166A1 (en) * 1999-08-24 2003-07-10 Sonia Cunningham Polynucleotide encoding a human junctional adhesion protein (JAM2)
IL148544A0 (en) 1999-09-24 2002-09-12 Genentech Inc Tyrosine derivatives
US6534513B1 (en) * 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
DE19950862C5 (de) 1999-10-21 2004-02-26 Lucas Varity Gmbh Betätigungseinheit für eine elektronisch gesteuerte Fahrzeugbremsanlage
WO2001032610A1 (fr) 1999-10-29 2001-05-10 Kaken Pharmaceutical Co., Ltd. Derive d'uree, son procede de production, et produit pharmaceutique contenant ce derive d'uree
JP4788939B2 (ja) 1999-11-18 2011-10-05 味の素株式会社 新規フェニルアラニン誘導体
ATE357433T1 (de) 1999-12-06 2007-04-15 Hoffmann La Roche 4-pyrimidinyl-n-acyl-l-phenylanine
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
NZ518888A (en) 1999-12-06 2004-02-27 F 4-pyridinyl-N-acyl-L-phenylalanines
US6388084B1 (en) * 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
US6849639B2 (en) * 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
CA2394431C (en) * 1999-12-16 2015-06-30 Jane Relton Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
JP2003519697A (ja) * 1999-12-28 2003-06-24 ファイザー・プロダクツ・インク 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のｖｌａ−４依存性細胞結合阻害薬
EP1253923A1 (en) 2000-01-28 2002-11-06 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
US6579889B2 (en) * 2000-06-22 2003-06-17 Merck & Co., Inc. Substituted isonipecotyl derivatives as inhibitors of cell adhesion
US6403584B1 (en) * 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
WO2002008202A2 (en) 2000-07-21 2002-01-31 Elan Pharmaceuticals, Inc. Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by vla-4
US7015216B2 (en) * 2000-07-21 2006-03-21 Elan Pharmaceuticals, Inc. Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors
AU7874001A (en) 2000-08-18 2002-03-04 Ajinomoto Kk Novel phenylalanine derivatives
US6709192B2 (en) 2000-09-05 2004-03-23 The Fort Miller Group, Inc. Method of forming, installing and a system for attaching a pre-fabricated pavement slab to a subbase and the pre-fabricated pavement slab so formed
CA2422135A1 (en) 2000-09-14 2003-03-13 Toray Industries, Inc. Urea derivatives and adhesion molecule inhibitors containing the same as effective ingredients
GB0028844D0 (en) * 2000-11-27 2001-01-10 Celltech Chiroscience Ltd Chemical compounds
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
US6559174B2 (en) * 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
JP4164871B2 (ja) 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体

Also Published As

Publication number Publication date
NO20026252D0 (no) 2002-12-27
WO2002002556A2 (en) 2002-01-10
NZ523852A (en) 2004-11-26
MXPA03000814A (es) 2004-11-01
US20020091115A1 (en) 2002-07-11
IL154053A0 (en) 2003-07-31
HUP0301195A2 (hu) 2003-08-28
EP1303492A2 (en) 2003-04-23
CA2415088A1 (en) 2002-01-10
YU98902A (sh) 2006-05-25
HK1052343A1 (zh) 2004-02-06
AR031853A1 (es) 2003-10-08
KR20030014287A (ko) 2003-02-15
JP2004506612A (ja) 2004-03-04
RU2003102631A (ru) 2004-09-27
AU2001273095A1 (en) 2002-01-14
CN1449385A (zh) 2003-10-15
WO2002002556A3 (en) 2002-07-18
PL359997A1 (en) 2004-09-06
US6960597B2 (en) 2005-11-01
NO20026252L (no) 2003-02-26

Similar Documents

Publication Publication Date Title
BR0112359A (pt) Derivados de aminoácidos aza-bicìclicos ligados por ponte como antagonistas de integrina alfa4
ATE212978T1 (de) Para-substituierte phenylpropansäure derivate als integrin-antagonisten
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
ES2162676T3 (es) Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
BG66085B1 (bg) Фенилаланинови производни
DE60103050D1 (de) Spiro[2.4]heptanaminocarbonsäure und ihre derivate
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
BR0210538A (pt) Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
BR0315681A (pt) Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável
BR9915403A (pt) Antagonistas receptores iii de 4-aroil-piperidin-ccr-3
KR970705556A (ko) 알레르기성 질환 치료에 유용한 신규 치환된 피페리딘(Novel substituted piperidines useful for the treatment of allergic diseases)
NO983190L (no) Nye N-(arylsulfonyl)aminosyre-derivater med bradykinin-reseptor-affinitet
BR9915735A (pt) Antagonistas receptores de ccr-3 de piperidina
ATE393147T1 (de) Kondensierte cycloheptan- und kondensierte azacycloheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
BR9908470A (pt) Composto, composição farmacêutica, e, processo para tratar condições mediadas pela inegrina avb3 em um mamìfero em necessidade de tal tratamento
BR9910130A (pt) Derivados de cubana como antagonistas de receptor de glutamato metabotrópico e processo para a sua preparação
NO973652L (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreseptor-antagonist
DE60111464D1 (de) Azabicycloalkan-Derivate zur Verwendung als Inhibitoren der Serotonin-Wiederaufnahme und als 5HT2a Antagonisten
BRPI0513912A (pt) derivados de amida de ácido cinurênico como antagonistas do receptor nr2b
TR200103789T2 (tr) Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller.
BR0214582A (pt) Derivados de piperazina para uso como antagonista do receptor ccr-3 no tratamento de asma

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON (US)

Free format text: TRANSFERIDO DE: ORTHO-MCNEIL PHARMACEUTICAL, INC.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 453/06; A61P 29/00, 11/06, 9/10, 17/06, 19/02, 37/02

Ipc: C07D 453/06 (2011.01), A61P 29/00 (2011.01), A61P

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2125 DE 27/09/2011.